ExpressionEdits

The company's core business revolves around its proprietary 'intronization' technology, which redesigns artificial genes (transgenes) to better mimic their natural counterparts, thereby improving protein expression levels. ExpressionEdits utilizes a computational platform called the Genetic Syntax Engine, which employs artificial intelligence and machine learning to analyze biological data and strategically incorporate introns—non-coding DNA sequences—into transgene designs. This process enhances the stability and export of RNA, enabling the production of complex proteins that have historically been difficult or impossible to manufacture at scale. The business model includes developing an internal pipeline of protein-based therapeutics and forming commercial partnerships. A significant milestone was a partnership and licensing agreement with Boehringer Ingelheim to develop novel gene therapies for two undisclosed targets. The company primarily serves the cell and gene therapy markets, a sector valued at over $20 billion.

The company's primary focus is on recombinant proteins and gene therapies that face manufacturing challenges with existing technologies. By improving protein yields, the technology allows for lower therapeutic doses, which can minimize toxicity and expand design options for therapies that were previously limited by poor expression. A key achievement was securing a $13 million seed funding round in May 2024, co-led by Octopus Ventures and redalpine, to accelerate preclinical studies and pipeline development. This funding enables ExpressionEdits to tackle the production of therapeutics for which the industry is currently reliant on human plasma, a practice with risks related to disease transmission and supply chain fragility.